{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T03:24:40Z","timestamp":1773285880866,"version":"3.50.1"},"reference-count":42,"publisher":"American Diabetes Association","issue":"6","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,6,1]]},"abstract":"<jats:p>Computer simulation models are mathematical equations combined in a structured framework to represent some real or hypothetical system. One of their uses is to allow the projection of short-term data from clinical trials to evaluate clinical outcomes and costs over a long-term period. This technology is becoming increasingly important to assist decision making in modern medicine in situations where there is a paucity of long-term clinical trial data, as recently acknowledged in the American Diabetes Association Consensus Panel Guidelines for Computer Modeling of Diabetes and its Complications. The Mount Hood Challenge Meetings provide a forum for computer modelers of diabetes to discuss and compare models and identify key areas of future development to advance the field. The Fourth Mount Hood Challenge in 2004 was the first meeting of its kind to ask modelers to perform simulations of outcomes for patients in published clinical trials, allowing comparison against \u201creal life\u201d data. Eight modeling groups participated in the challenge. Each group was given three of the following challenges: to simulate a trial of type 2 diabetes (CARDS [Collaborative Atorvastatin Diabetes Study]); to simulate a trial of type 1 diabetes (DCCT [Diabetes Control and Complications Trial]); and to calculate outcomes for a hypothetical, precisely specified patient (cross-model validation). The results of the models varied from each other and for methodological reasons, in some cases, from the published trial data in important ways. This approach of performing systematic comparisons and validation exercises has enabled the identification of key differences among the models, as well as their possible causes and directions for improvement in the future.<\/jats:p>","DOI":"10.2337\/dc07-9919","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T20:13:49Z","timestamp":1180124029000},"page":"1638-1646","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":172,"title":["Computer Modeling of Diabetes and Its Complications"],"prefix":"10.2337","volume":"30","author":[{"name":"The Mount Hood 4 Modeling Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","reference":[{"key":"2022031221150445200_R1","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Consensus Panel: Guidelines for computer modeling of diabetes and its complications (Consensus Statement). Diabetes Care\u200827: 2262\u20132265, 2004","DOI":"10.2337\/diacare.27.9.2262"},{"key":"2022031221150445200_R2","doi-asserted-by":"crossref","unstructured":"Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ, Matthews DR, Stratton IM, Holman RR: A model to estimate the lifetime health outcomes of patients with type 2 diabetes, UK Prospective Diabetes Study (UKPDS): the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia\u200847:1747\u20131759, 2004","DOI":"10.1007\/s00125-004-1527-z"},{"key":"2022031221150445200_R3","doi-asserted-by":"crossref","unstructured":"Stevens RJ, Kothari V, Adler AI, Stratton IM, Holman RR: The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond )\u2008101:671\u2013679, 2001","DOI":"10.1042\/cs1010671"},{"key":"2022031221150445200_R4","doi-asserted-by":"crossref","unstructured":"Kothari V, Stevens RJ, Adler AI, Stratton IM, Manley SE, Neil HA, Holman RR: UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke\u200833:1776\u20131781, 2002","DOI":"10.1161\/01.STR.0000020091.07144.C7"},{"key":"2022031221150445200_R5","doi-asserted-by":"crossref","unstructured":"Stevens RJ, Coleman RL, Adler AI, Stratton IM, Matthews DR, Holman RR: Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. Diabetes Care\u200827:201\u2013207, 2004","DOI":"10.2337\/diacare.27.1.201"},{"key":"2022031221150445200_R6","doi-asserted-by":"crossref","unstructured":"Stevens RJ: Evaluation of methods for interval estimation of model outputs, with application to survival models. J Appl Stat\u200830:967\u2013981, 2003","DOI":"10.1080\/0266476032000076100"},{"key":"2022031221150445200_R7","doi-asserted-by":"crossref","unstructured":"Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA: The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin\u200820(Suppl. 1):S5\u2013S26, 2004","DOI":"10.1185\/030079904X1980"},{"key":"2022031221150445200_R8","doi-asserted-by":"crossref","unstructured":"Palmer AJ, Roze S, Valentine W, Minshall M, Foos V, Lurati F, Lammert M, Spinas GA: Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin\u200820(Suppl. 1):S27\u2013S40, 2004","DOI":"10.1185\/030079904X1980"},{"key":"2022031221150445200_R9","doi-asserted-by":"crossref","unstructured":"Hoerger TJ, Harris R, Hicks KA, Donahue K, Sorensen S, Engelgau M: Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Ann Intern Med\u2008140:689\u2013699, 2004","DOI":"10.7326\/0003-4819-140-9-200405040-00008"},{"key":"2022031221150445200_R10","doi-asserted-by":"crossref","unstructured":"Earnshaw SR, Richter A, Sorensen SW, Hoerger TJ, Hicks KA, Engelgau M, Thompson T, Narayan KM, Williamson DF, Gregg E, Zhang P: Optimal allocation of resources across four interventions for type 2 diabetes. Med Decis Making\u200822(Suppl. 5):S80\u2013S91, 2002","DOI":"10.1177\/027298902237704"},{"key":"2022031221150445200_R11","doi-asserted-by":"crossref","unstructured":"Eddy DM, Schlessinger L: Archimedes: a trial-validated model of diabetes. Diabetes Care\u200826:3093\u20133101, 2003","DOI":"10.2337\/diacare.26.11.3093"},{"key":"2022031221150445200_R12","doi-asserted-by":"crossref","unstructured":"Eddy DM, Schlessinger L: Validation of the Archimedes diabetes model. Diabetes Care\u200826:3102\u20133110, 2003","DOI":"10.2337\/diacare.26.11.3102"},{"key":"2022031221150445200_R13","unstructured":"Mount Hood 4 Web site [Internet]. Available from http:\/\/www.thecenter.ch\/mounthood4\/mounthood.asp. Accessed 24 February 2005"},{"key":"2022031221150445200_R14","doi-asserted-by":"crossref","unstructured":"Colhoun HM, Thomason MJ, Mackness MI, Maton SM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Fuller JH: Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Diabet Med\u200819:201\u2013211, 2002","DOI":"10.1046\/j.1464-5491.2002.00643.x"},{"key":"2022031221150445200_R15","unstructured":"Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil AW, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH: The Collaborative Atorvastatin Diabetes Study (CARDS): effectiveness of lipid lowering for the primary prevention of major cardiovascular events in diabetes. Late-breaking abstract presented at the American Diabetes Association 64th Annual Scientific Sessions, 4\u20138 June 2004, at the Orange County Convention Center, Orlando, Florida"},{"key":"2022031221150445200_R16","doi-asserted-by":"crossref","unstructured":"Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet\u2008364:685\u2013696, 2004","DOI":"10.1016\/S0140-6736(04)16895-5"},{"key":"2022031221150445200_R17","doi-asserted-by":"crossref","unstructured":"American Diabetes Association: The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes\u200845:1289\u20131298, 1996","DOI":"10.2337\/diabetes.45.10.1289"},{"key":"2022031221150445200_R18","doi-asserted-by":"crossref","unstructured":"American Diabetes Association: The Diabetes Control and Complications Trial (DCCT): design and methodological considerations for the feasibility phase: the DCCT Research Group. Diabetes\u200835:530\u2013545, 1986","DOI":"10.2337\/diabetes.35.5.530"},{"key":"2022031221150445200_R19","doi-asserted-by":"crossref","unstructured":"American Diabetes Association: Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care\u200818:361\u2013376, 1995","DOI":"10.2337\/diacare.18.3.361"},{"key":"2022031221150445200_R20","doi-asserted-by":"crossref","unstructured":"The DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Group. N Engl J Med\u2008329:977\u2013986, 1993","DOI":"10.1056\/NEJM199309303291401"},{"key":"2022031221150445200_R21","doi-asserted-by":"crossref","unstructured":"The DCCT Research Group: Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int\u200847:1703\u20131720, 1995","DOI":"10.1038\/ki.1995.236"},{"key":"2022031221150445200_R22","doi-asserted-by":"crossref","unstructured":"The DCCT Research Group: The effect of intensive diabetes therapy on the development and progression of neuropathy: the Diabetes Control and Complications Trial Research Group. Ann Intern Med\u2008122:561\u2013568, 1995","DOI":"10.7326\/0003-4819-122-8-199504150-00001"},{"key":"2022031221150445200_R23","doi-asserted-by":"crossref","unstructured":"The DCCT Research Group: The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. Arch Ophthalmol\u2008113:36\u201351, 1995","DOI":"10.1001\/archopht.1995.01100010038019"},{"key":"2022031221150445200_R24","doi-asserted-by":"crossref","unstructured":"Persson U, Willis M, Odegaard K, Apelqvist J: The Cost-effectiveness of Treating Diabetic Lower Extremity Ulcers with Becaplermin (Regranex): a core model with an application using Swedish cost data. Value Health\u20083(Suppl. 1):39\u201346, 2000","DOI":"10.1046\/j.1524-4733.2000.36027.x"},{"key":"2022031221150445200_R25","doi-asserted-by":"crossref","unstructured":"Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR: Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int\u200863:225\u2013232, 2003","DOI":"10.1046\/j.1523-1755.2003.00712.x"},{"key":"2022031221150445200_R26","doi-asserted-by":"crossref","unstructured":"Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23) BMJ\u2008316:823\u2013828, 1998","DOI":"10.1136\/bmj.316.7134.823"},{"key":"2022031221150445200_R27","doi-asserted-by":"crossref","unstructured":"Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ\u2008321:405\u2013412, 2000","DOI":"10.1136\/bmj.321.7258.405"},{"key":"2022031221150445200_R28","doi-asserted-by":"crossref","unstructured":"Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, Matthews DR: UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia\u200844:156\u2013163, 2001","DOI":"10.1007\/s001250051594"},{"key":"2022031221150445200_R29","unstructured":"Coleman RL, Stevens RJ, Matthews DR, Holman RR: A cardiovascular risk calculator for type 2 diabetes (Abstract). Diabetes\u200854(Suppl. 1):A172, 2005"},{"key":"2022031221150445200_R30","doi-asserted-by":"crossref","unstructured":"Mu\u0308ller E, Maxion-Bergemann S, Gultyaev D, Walzer S, Bergemann R: EAGLE Diabetes Model: basic features and internal validation of simulating long-term diabetic outcomes and related costs (Abstract). Value Health\u20087:745, 2004","DOI":"10.1016\/S1098-3015(10)65977-3"},{"key":"2022031221150445200_R31","unstructured":"Mu\u0308ller E, Maxion-Bergemann S, Bolinder B, Gerber RA, Bergemann R: EAGLE\u2013Economic Assessment of Glycemic control and Longterm Effects: a computer simulation model for diabetes mellitus type 1 and type 2 (Abstract). Diabetologia\u200847:A355, 2004"},{"key":"2022031221150445200_R32","doi-asserted-by":"crossref","unstructured":"Mueller E, Maxion-Bergemann S, Gultyaev D, Walzer S, Freemantle N, Mathieu C, Bolinder B, Gerber R, Kvasz M, Bergemann R: Development and validation of the Economic Assessment of Glycemic Control and Long-Term Effects of diabetes (EAGLE) model. Diabetes Technol Ther\u20088:219\u2013236, 2006","DOI":"10.1089\/dia.2006.8.219"},{"key":"2022031221150445200_R33","doi-asserted-by":"crossref","unstructured":"Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA\u2008287:2542\u20132551, 2002","DOI":"10.1001\/jama.287.19.2542"},{"key":"2022031221150445200_R34","doi-asserted-by":"crossref","unstructured":"Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, Hamman RF, Ackermann RT, Engelgau MM, Ratner RE: The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med\u2008142:323\u2013332, 2005","DOI":"10.7326\/0003-4819-142-5-200503010-00007"},{"key":"2022031221150445200_R35","unstructured":"Kaiser Permenante: Archimedes Model [Internet], 2005. Available from http:\/\/www.archimedesmodel.com. Accessed 11 September 2005"},{"key":"2022031221150445200_R36","unstructured":"Palmer AJ, Roze S, Lammert M, Valentine WJ, Nicklasson L: The impact of using either Framingham or United Kingdom Prospective Diabetes Study risk formula in diabetes health economic modeling. Abstract presented at the International Society for Economics and Outcomes Research (ISPOR) 9th Annual International Meeting Program Presentation, 16\u201319 May 2004, at the Crystal Gateway Marriott, Arlington, Virginia"},{"key":"2022031221150445200_R37","doi-asserted-by":"crossref","unstructured":"Guzder RN, Gatling W, Mullee MA, Mehta RL, Byrne CD: Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed type 2 diabetes: results from a United Kingdom study. Diabet Med\u200822:554\u2013562, 2005","DOI":"10.1111\/j.1464-5491.2005.01494.x"},{"key":"2022031221150445200_R38","doi-asserted-by":"crossref","unstructured":"Yeo WW, Yeo KR: Predicting CHD risk in patients with diabetes mellitus. Diabet Med\u200818:341\u2013344, 2001","DOI":"10.1046\/j.1464-5491.2001.00510.x"},{"key":"2022031221150445200_R39","doi-asserted-by":"crossref","unstructured":"McEwan P, Williams JE, Griffiths JD, Bagust A, Peters JR, Hopkinson P, Currie CJ: Evaluating the performance of the Framingham risk equations in a population with diabetes. Diabet Med\u200821:318\u2013323, 2004","DOI":"10.1111\/j.1464-5491.2004.01139.x"},{"key":"2022031221150445200_R40","doi-asserted-by":"crossref","unstructured":"Weinstein S: Fifty years of somatosensory research: from the Semmes-Weinstein monofilaments to the Weinstein Enhanced Sensory Test. J Hand Ther\u20086:11\u201322, 1993","DOI":"10.1016\/S0894-1130(12)80176-1"},{"key":"2022031221150445200_R41","doi-asserted-by":"crossref","unstructured":"Chatfield C: Model uncertainty, data mining and statistical inference. J R Stat Ser Stat Soc A:419\u2013466, 1995","DOI":"10.2307\/2983440"},{"key":"2022031221150445200_R42","doi-asserted-by":"crossref","unstructured":"Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med\u2008353:1784\u20131792, 2005","DOI":"10.1056\/NEJMoa050518"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/30\/6\/1638\/597873\/zdc00607001638.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/30\/6\/1638\/597873\/zdc00607001638.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T23:24:13Z","timestamp":1647127453000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/30\/6\/1638\/30690\/Computer-Modeling-of-Diabetes-and-Its"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,1]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,6,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc07-9919","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,1]]}}}